ストックスクリーナーアプリを入手
20.86
2.81%
0.57
アフターアワーズ：
20.70
-0.16
-0.77%
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KALV SEC FilingsKalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data - Sahm
Inflation Data: Is KalVista Pharmaceuticals Inc subject to activist investor interestDay Trade & Growth Focused Investment Plans - baoquankhu1.vn
Market Moves: Is KalVista Pharmaceuticals Inc impacted by rising ratesWeekly Investment Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
KalVista Pharmaceuticals Inc (HAM:4XC1) Valuation - GuruFocus
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN
Behavioral Patterns of KALV and Institutional Flows - Stock Traders Daily
Investor Mood: Is KalVista Pharmaceuticals Inc forming higher highs and higher lows2026 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Merger Talk: Will KalVista Pharmaceuticals Inc face regulatory challenges2026 Price Momentum & High Accuracy Investment Signals - baoquankhu1.vn
Ekterly pill may change how families treat HAE attacks in young children - Angioedema News
Death Cross: Can KalVista Pharmaceuticals Inc expand its profit marginsShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Breakout Zone: Can KalVista Pharmaceuticals Inc deliver consistent dividendsProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - joplinglobe.com
KALV PE Ratio & Valuation, Is KALV Overvalued - Intellectia AI
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive (KALV) - Seeking Alpha
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Big Picture: Will KalVista Pharmaceuticals Inc face regulatory challengesMarket Performance Recap & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold - marketbeat.com
Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next - Sahm
A Look At KalVista Pharmaceuticals (KALV) Valuation After Positive KONFIDENT KID EKTERLY Trial Update - Sahm
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year HighShould You Buy? - MarketBeat
KALV Should I Buy - Intellectia AI
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial - Yahoo Finance
KalVista Pharmaceuticals Stock: Positive Pediatric Trial Data Positions KALV for HAE Market Expansio - AD HOC NEWS
Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista reports interim data on pediatric HAE treatment trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - BioSpace
(KALV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
KalVista (KALV) Announces Positive Interim Results from KONFIDEN - GuruFocus
KalVista Announces Positive Interim Data for Pediatric HAE Treatment - National Today
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data - The National Law Review
KalVista reports interim data on pediatric HAE treatment trial - Investing.com
HC Wainwright Has Negative Forecast for KALV FY2028 Earnings - MarketBeat
KalVista Pharmaceuticals Inc Stock Historical Valuations | HAM:4XC1 - GuruFocus
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells 174,645 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to Buy at Wall Street Zen - MarketBeat
Venrock healthcare sells KalVista (KALV) shares for $3.69 million - Investing.com UK
Venrock healthcare sells KalVista (KALV) shares for $3.69 million By Investing.com - Investing.com South Africa
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - stocktitan.net
KalVista Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:KALV) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative - simplywall.st
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Achieve Life Sciences (ACHV) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 8.7% on Analyst Upgrade - MarketBeat
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target - Investing.com UK
KalVista Pharmaceuticals Inc Stock Baskets | HAM:4XC1 - gurufocus.com
Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch By Investing.com - Investing.com Australia
KALV: Stifel Raises Price Target to $42 and Maintains Buy Rating - GuruFocus
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):